Figure 1.
Identification of antiglioblastoma drug candidates. (A) Results of a high throughput screen of over 3000 compounds using a bioluminescence-based assay quantifying death receptor expression levels, and converting total flux into z-scores and (B) quantification of the levels of death receptor expression induced by the five lead compounds (100 nm) via bioluminescence imaging. (C) IC50 values found for the five lead compounds against normal human astrocytes (NHA) and glioblastoma cell lines (NS039 and T4213) after 72 h of treatment and (D) validation of the in vivo antiglioblastoma activity of quisinostat by bioluminescence imaging.